TechBio Talks Episode 6: Breyer Capital's Morgan Cheatham with Host Najat Khan

In this episode of TechBio Talks, host Najat Khan, PhD, CEO and President of Recursion, talks to Dr. Morgan Cheatham, Partner and Head of Healthcare and Life Sciences at Breyer Capital, about how artificial intelligence and clinical data are converging to transform the measurement of human physiology and disease. Morgan is a physician, medical geneticist, and investor who has spent nearly a decade backing category-defining companies spanning diagnostics, therapeutics, and care delivery. They discuss how AI is reshaping the fundamentals of biotech value creation, the vital concept of "modality market fit" for matching therapeutic architectures to patient tolerance, and why the ultimate moat in AI drug discovery is closing the loop between the wet lab, dry lab, and the clinic. Their conversation also covers how recasting medicine as an information science can collapse the barrier between scientific discovery and patient care delivery. Chapters: 00:00 Introduction 00:57 The Role of Medical Geneticists in Healthcare 03:47 Investing: A Dual Perspective 04:46 Fundamentals of Biotech Value Creation 08:43 Private vs. Public Markets & Discontinuous Tech 12:00 Building the Ultimate Data Moat 13:43 AI as Measurement Tool in Healthcare 18:10 Unlocking Clinical Biobanks 20:42 Precision Therapy & Early Patient Selection 23:48 Defining Modality Market Fit 26:45 Designing for the Patient Experience 29:35 Medicine as an Information Science 31:42 Root Cause Analysis in Medicine and Innovation 33:42 Closing